LE PERSPECTIVE / THE STORY

Science Corporation has raised $400 million in a Series D to expand PRIMA, its retinal implant for people with severe central vision loss, and fund research on neural interfaces built with living neurons.

Founded by former Neuralink president Max Hodak, Science plans to expand PRIMA across Europe, prepare for a US launch, and grow manufacturing operations. Investors include Khosla Ventures, Y Combinator, Tenet Healthcare, Ackman Oxman Institute, 885 Capital and PLC Neurotech.

From the Lab to Patients
The near-term challenge is turning a clinical breakthrough into a treatment patients can actually access. European authorization is in place, but US sales still require FDA approval.

PRIMA pairs a light-powered retinal implant with specialized glasses that project images onto the chip. It stimulates surviving retinal cells, helping people with advanced macular degeneration read letters, numbers and words.

PRIMA received a European CE mark in July. In a study of 38 patients, 80% had meaningful visual-acuity improvement at 12 months, according to Science. The company is pursuing FDA authorization through a Humanitarian Device Exemption.

Science is separately developing biohybrid interfaces that use engineered neurons to connect with the brain’s circuitry. That technology remains experimental.

The round funds two distinct ambitions: scaling a medical device for patients today, and testing whether living-neuron interfaces can become tomorrow’s treatments.

Get stories like this in your inbox every week. Subscribe to The Week in Perspective.